- NervGen (NGEN) announced that the USPTO has issued US Patent No. 11,497,812 to Case Western Reserve University
- NervGen has an exclusive worldwide license to this patent and related proprietary technology
- This patent is an important milestone in protecting the commercial potential of NVG-291
- NervGen holds exclusive worldwide rights to NVG-291, a therapeutic targeting pathogenic mechanisms that interfere with nervous system repair
- NervGen Pharma is a clinical-stage biotech company dedicated to developing innovative solutions for the repair of nervous system damage
- NervGen Pharma Corp. (NGEN) is down 2.86 per cent on the day, trading at C$1.70 per share at 1:30 pm ET
NervGen (NGEN) announced that the USPTO has issued US Patent No. 11,497,812 to Case Western Reserve University.
NervGen has an exclusive worldwide license to this patent and related proprietary technology, which forms the technological foundation of its NVG-291 drug development program.
“This patent issuance by the USPTO is an important milestone in protecting the commercial potential of NVG-291 and also demonstrates the strong commitment by Case Western Reserve University and NervGen to protecting the innovation and commercial opportunity of our entire technology portfolio,” stated Bill Radvak, NervGen’s Executive Chairman & Interim CEO.
This new patent is the third US patent to be issued covering the proposed NVG-291 product composition. Additional US-granted patents and multiple pending patent applications cover a range of clinical indications for NVG-291. NVG-291 is also covered by granted patents and pending patent applications around the world in major commercial markets.
NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic targeting pathogenic mechanisms that interfere with nervous system repair. NVG-291-R, a rodent analog of NVG-291, has been shown to promote nervous system repair and functional recovery in animal models of spinal cord injury, peripheral nerve injury, multiple sclerosis and stroke through enhanced plasticity, axonal regeneration, and remyelination.
NervGen is a clinical-stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial.
NervGen Pharma Corp. (NGEN) is down 2.86 per cent on the day, trading at C$1.70 per share at 1:30 pm ET.
